Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$7.4 million.

  • Inmune Bio's Income from Continuing Operations rose 3950.02% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.4 million, marking a year-over-year decrease of 2365.75%. This contributed to the annual value of -$42.6 million for FY2024, which is 4207.88% down from last year.
  • Latest data reveals that Inmune Bio reported Income from Continuing Operations of -$7.4 million as of Q3 2025, which was up 3950.02% from -$24.6 million recorded in Q2 2025.
  • Inmune Bio's Income from Continuing Operations' 5-year high stood at -$4.5 million during Q1 2021, with a 5-year trough of -$24.6 million in Q2 2025.
  • For the 5-year period, Inmune Bio's Income from Continuing Operations averaged around -$8.9 million, with its median value being -$8.4 million (2023).
  • The largest annual percentage gain for Inmune Bio's Income from Continuing Operations in the last 5 years was 3950.02% (2025), contrasted with its biggest fall of 14907.25% (2025).
  • Quarter analysis of 5 years shows Inmune Bio's Income from Continuing Operations stood at -$9.0 million in 2021, then soared by 37.52% to -$5.6 million in 2022, then tumbled by 48.51% to -$8.4 million in 2023, then fell by 12.98% to -$9.5 million in 2024, then grew by 21.49% to -$7.4 million in 2025.
  • Its Income from Continuing Operations stands at -$7.4 million for Q3 2025, versus -$24.6 million for Q2 2025 and -$9.9 million for Q1 2025.